RT Journal Article
SR Electronic
T1 PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
JF Cancer Biology and Medicine
JO Cancer Biol Med
FD China Anti-Cancer Association
SP 116
OP 123
DO 10.20892/j.issn.2095-3941.2017.0086
VO 15
IS 2
A1 Long Jia
A1 Qi Zhang
A1 Rongxin Zhang
YR 2018
UL http://www.cancerbiomed.org/content/15/2/116.abstract
AB Cancer immunotherapy has greatly advanced in recent years, and PD-1/PD-L1 blocking therapy has become a major pillar of immunotherapy. Successful clinical trials of PD-1/PD-L1 blocking therapies in cancer treatments have benefited many patients, which promoted the Food and Drug Administration (FDA) approval of PD-1/PD-L1 blocking drugs. In this review, we provide a detailed introduction of five PD-1/PD-L1 blocking drugs, with indications and studies, as a valuable reference for doctors and medical investigators. Moreover, the characteristics of PD-1/PD-L1 blocking therapies, including their universality and sustainability, are discussed in this review. Furthermore, we also discuss and predict the possibility of PD-L1 as an indication marker of PD-1/PD-L1 blocking therapy for pan-cancer treatment, and the current status of combination therapies.